|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0016360,
umls-concept:C0030705,
umls-concept:C0045093,
umls-concept:C0069717,
umls-concept:C0205179,
umls-concept:C0282460,
umls-concept:C0332174,
umls-concept:C0574032,
umls-concept:C0861727,
umls-concept:C1825590,
umls-concept:C2697648
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2007-1-15
|
|
pubmed:abstractText |
Combinations of gemcitabine-oxaliplatin, gemcitabine-5-fluorouracil (5-FU) and 5-FU-oxaliplatin have synergistic activity and nonoverlapping adverse effect profiles. This trial assessed efficacy and safety of the triple combination gemcitabine-oxaliplatin and infusional 5-FU in patients with locally advanced (n=11) or metastatic (n=32) pancreatic adenocarcinoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
82-7
|
|
pubmed:meshHeading |
pubmed-meshheading:17030546-Adenocarcinoma,
pubmed-meshheading:17030546-Aged,
pubmed-meshheading:17030546-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17030546-Deoxycytidine,
pubmed-meshheading:17030546-Disease Progression,
pubmed-meshheading:17030546-Disease-Free Survival,
pubmed-meshheading:17030546-Female,
pubmed-meshheading:17030546-Fluorouracil,
pubmed-meshheading:17030546-Humans,
pubmed-meshheading:17030546-Infusions, Intravenous,
pubmed-meshheading:17030546-Male,
pubmed-meshheading:17030546-Middle Aged,
pubmed-meshheading:17030546-Organoplatinum Compounds,
pubmed-meshheading:17030546-Pancreatic Neoplasms,
pubmed-meshheading:17030546-Quality of Life,
pubmed-meshheading:17030546-Survival Rate,
pubmed-meshheading:17030546-Time Factors,
pubmed-meshheading:17030546-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
|
|
pubmed:affiliation |
First Department of Medicine, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany. anna-dorothea.wagner@gmx.de
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
